About Moleculin Biotech Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://moleculin.com/
Frequently Asked Questions
What is the 52-week range for MBRX?
The 52-week high is $15.75 and the 52-week low is $0.1614.
What is the P/E ratio for MBRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for MBRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -35.39%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.46.
Analyst Recommendation Trends
Wall Street analyst consensus for MBRX over the last few months:
Latest MBRX News
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refractory acute myeloid leukemiaFull Part A population expected to provide important efficacy insights across subjects who relapsed from or were refractory to first line (1L) AML treatment, including intensive 7+3 and venetoclax-based regimensExpect final Part A dataset to approximate 50/50 between 1L 7+3 and venetoclax-based regimensAbsence of cardiotoxicity continues to di
Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia
Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits – Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardia
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is parti
Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposom
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are gapping on Monday?
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47% to $106.19.
Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August
U.S. stocks rose Monday, led by the Dow’s 200-point gain; communication shares climbed, energy fell, while oil dropped and Greenland stocks surged.
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap stands at
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
Access the video webcast here HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments. The on-d
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-03 | KLEMP WALTER V | +1,599,999 | - | - |
| 2026-08-03 | KLEMP WALTER V | +533,333 | - | - |
| 2026-08-03 | Foster Jonathan P. | +879,999 | - | - |
| 2026-08-03 | Foster Jonathan P. | +293,333 | - | - |
| 2026-08-03 | PICKER DONALD H | +519,999 | - | - |
| 2026-08-03 | PICKER DONALD H | +173,333 | - | - |
| 2026-06-22 | KLEMP WALTER V | -360 | - | - |
| 2026-06-22 | KLEMP WALTER V | -88 | $3.12 | $275 |
| 2026-06-22 | KLEMP WALTER V | +360 | - | - |
| 2026-06-22 | Foster Jonathan P. | -174 | - | - |
| 2026-06-22 | Foster Jonathan P. | -41 | $3.12 | $128 |
| 2026-06-22 | Foster Jonathan P. | +174 | - | - |
| 2026-06-22 | PICKER DONALD H | -71 | - | - |
| 2026-06-22 | PICKER DONALD H | -21 | $3.12 | $66 |
| 2026-06-22 | PICKER DONALD H | +71 | - | - |
| 2026-06-20 | KLEMP WALTER V | -150 | - | - |
| 2026-06-20 | KLEMP WALTER V | -37 | $2.88 | $107 |
| 2026-06-20 | KLEMP WALTER V | +150 | - | - |
| 2026-06-20 | Foster Jonathan P. | -109 | - | - |
| 2026-06-20 | Foster Jonathan P. | -31 | $2.88 | $89 |
| 2026-06-20 | Foster Jonathan P. | +109 | - | - |
| 2026-06-20 | PICKER DONALD H | -44 | - | - |
| 2026-06-20 | PICKER DONALD H | -13 | $2.88 | $37 |
| 2026-06-20 | PICKER DONALD H | +44 | - | - |
| 2025-11-12 | George Robert E. | +150,000 | - | - |
| 2025-11-12 | KLEMP WALTER V | +750,000 | - | - |
| 2025-11-12 | KLEMP WALTER V | +830,000 | - | - |
| 2025-11-12 | Yan Joy | +150,000 | - | - |
| 2025-11-12 | Climaco John M | +150,000 | - | - |
| 2025-11-12 | Foster Jonathan P. | +400,000 | - | - |
| 2025-11-12 | Foster Jonathan P. | +600,000 | - | - |
| 2025-11-12 | Cermak Elizabeth | +150,000 | - | - |
| 2025-11-12 | PICKER DONALD H | +200,000 | - | - |
| 2025-11-12 | PICKER DONALD H | +200,000 | - | - |
| 2025-11-12 | CANNON MICHAEL D | +150,000 | - | - |
| 2025-11-04 | KLEMP WALTER V | -28,750 | - | - |
| 2025-11-04 | KLEMP WALTER V | -7,001 | $0.497 | $3,479 |
| 2025-11-04 | KLEMP WALTER V | +28,750 | - | - |
| 2025-11-04 | Foster Jonathan P. | -20,625 | - | - |
| 2025-11-04 | Foster Jonathan P. | -5,023 | $0.497 | $2,496 |
| 2025-11-04 | Foster Jonathan P. | +20,625 | - | - |
| 2025-11-04 | PICKER DONALD H | -8,750 | - | - |
| 2025-11-04 | PICKER DONALD H | -2,131 | $0.497 | $1,059 |
| 2025-11-04 | PICKER DONALD H | +8,750 | - | - |